Patents by Inventor Tina Stummann

Tina Stummann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • AGENTS, USES AND METHODS FOR TREATMENT
    Publication number: 20210292414
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
    Type: Application
    Filed: December 11, 2020
    Publication date: September 23, 2021
    Applicant: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren, Esben Trabjerg, Kasper Dyrberg Rand
  • Agents, uses and methods for treatment
    Patent number: 10894833
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: January 19, 2021
    Assignee: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren
  • AGENTS, USES AND METHODS FOR TREATMENT
    Publication number: 20190023788
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) and other neurodegenerative disorders such as Alzheimers disease (AD).
    Type: Application
    Filed: July 17, 2018
    Publication date: January 24, 2019
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Tina Stummann, Arnout Gerritsen, Edward van den Brink, Paul Parren